CAS: 676602-31-6; Methyl 3-Cyano-4-Fluorobenzoate

上下游产品

CAS号67-56-1 甲醇 | CAS号201230-82-2 carbon monoxide | CAS号179897-89-3 5-溴-2-氟苯腈 | CAS号171050-06-9 3-氰基-4-氟苯甲酸 | CAS号74-88-4 碘甲烷 | CAS号75-36-5 乙酰氯 | CAS号218301-22-5 2-氟-5-甲酰基苯腈 | CAS号258273-31-3 3-氰基-4-异丙氧基苯甲酸

2-氟-5-甲酰基苯腈置于重铬酸吡啶,乙酰氯体系中,用 Dmf (N,N-Dimethyl-Formamide) 作为反应溶剂,化学反应 48.0H,反应生成 3-氰基-4-氟苯甲酸甲酯
参考文献: Pyrrolopyrimidine Derivatives As Modulators Of Multi-Drug Resistance (Mdr)[fr] Derives Pyrrolopyrimidiniques Convenant Comme Modulateurs De La Multiresistance Aux Medicaments
标题: Pyrrolopyrimidine Derivatives As Modulators Of Multi-Drug Resistance (Mdr)[fr] Derives Pyrrolopyrimidiniques Convenant Comme Modulateurs De La Multiresistance Aux Medicaments
摘要:化合物是一种公式为(i)的吡咯吡嘧啶,其中r1从h,未取代或取代的cl-C6烷基,(ch2)nar1,(ch2)pnr4R5,卤素和(ch2)px中选择;r2为(ch2)parl;r3从h,未取代或取代的cl-C6烷基,(ch2)pz和(ch2)parl中选择;p为未取代或取代的不饱和5,6或7成员碳环或杂环;r4和r5相同或不同,从h,未取代或取代的cl-C6烷基,(ch2)nc3-C10环烷基,(ch2)nar1和(ch2)nor6中选择,或者r4和r5与它们连接的氮原子一起形成饱和的含氮五元或六元杂环,可能含有一个额外的杂原子,选择自o,N和s,未取代或取代;r6从h,未取代或取代的cl-C6烷基,C3-C10环烷基,(ch2)noc1-C6烷基,未取代或取代的(ch2)no(ch2)nar1,未取代或取代的(ch2)nco2C1-C6烷基和(ch2)nar1中选择;x从cn,叠氮,(ch2)nnhso2R6和(ch2)nnhcor6中选择;z从cn,Co2R6和conr4R5中选择;ar1当多个存在于给定的取代基组内时相同或不同,为未取代或取代的不饱和c6-C10成员碳环或未取代或取代的不饱和5-11成员杂环;p为1至6的整数;n当多个存在于给定的取代基组内时相同或不同,为0或1至6的整数;但是,公式(i)的吡咯吡嘧啶化合物不是1-(4-苄基哌嗪-1-基)-9H-2,4,9-三氮杂萘;其药学上可接受的盐具有作为mrp(多药耐药蛋白)抑制剂的活性,因此可用于调节多药耐药性,例如在增强化疗药物的细胞毒性方面.

专利信息

专利号:US-2025091989-A1
优先权日:2023-09-19
标 题 :Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.